Nama's AI scorecard currently rates ANI Pharmaceuticals Buy (7.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ANIP's P/E ratio?

ANI Pharmaceuticals trades at a trailing price-to-earnings ratio of 7.3.

When does ANIP report earnings?

ANI Pharmaceuticals's next scheduled report is on Feb 26, 2027. Analysts expect EPS of $2.82.

What is the ANIP price target?

The median analyst price target from 9 analysts is $104.00, with a range of $85.00 – $121.00.

Is ANIP Shariah compliant?

Nama's AAOIFI-style screen reads ANI Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

ANI Pharmaceuticals (ANIP)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

ANI Pharmaceuticals (ANIP) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.55B, a trailing price-to-earnings ratio of 7.3 and a free-cash-flow yield of 10.6%. Over the most recent reported fiscal year, revenue grew 43.8% and free cash flow per share grew 191.8%. Nama's AI scorecard rates it Buy, 7.8 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 7.8/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Trailing · -20.3% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-32.2%

How far the last close sits under the highest price of the past five years.

Market cap	$1.55B
Trailing P/E	7.3
Price / book	2.6
Price / sales	1.6
FCF yield	10.6%
Dividend yield	—
Gross margin	60.4%
Operating margin	13.3%
Net margin	11.1%
Revenue growth (YoY)	+43.8%
Revenue growth (3-yr annual)	+40.8%
EPS growth (YoY)	+51.4%
FCF/share growth (YoY)	+191.8%
Beta	0.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

ANIP earnings

Next report: Feb 26, 2027 (Q4 2026, EPS estimate $2.82). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$2.70	$2.18	+23.9%	$290.78M
Q2 2026	Aug 7, 2026	$2.21	$2.04	+8.3%	$266.04M
Q1 2026	May 8, 2026	$2.05	$1.30	+57.7%	$237.46M
Q4 2025	Feb 27, 2026	$2.33	$1.98	+17.7%	$247.06M

ANIP analyst price target

Median target $104.00 from 9 analysts, ranging $85.00 – $121.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live ANIP data on Nama Insights →

ANIP FAQ

Is ANIP a buy?: Nama's AI scorecard currently rates ANI Pharmaceuticals Buy (7.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ANIP's P/E ratio?: ANI Pharmaceuticals trades at a trailing price-to-earnings ratio of 7.3.
When does ANIP report earnings?: ANI Pharmaceuticals's next scheduled report is on Feb 26, 2027. Analysts expect EPS of $2.82.
What is the ANIP price target?: The median analyst price target from 9 analysts is $104.00, with a range of $85.00 – $121.00.
Is ANIP Shariah compliant?: Nama's AAOIFI-style screen reads ANI Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.